A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancerQingyuan Zhang, Huiping Li, Yuting Wang et al.|BMC Medicine|2022Cited by 37
No association of single nucleotide polymorphisms involved in GHRL and GHSR with cancer risk: A meta-analysisShengjie Zhu, Kai Wang, Bin Shao et al.|Cancer Biomarkers|2015Cited by 6